Use and Costs of Medical Foods and Convenience-Packaged Drugs in the California Workers' Compensation System

Tracy Kuo Lin, MSc, PhD, and Leslie Wilson, PhD

ABSTRACT

BACKGROUND: Sales of medical foods (MFs) and convenience packages (CPs) are projected to exceed \$2 billion in the United States, with an annual growth rate of 10%. Several studies have highlighted the rapid growth of MF use within the California Workers' Compensation System (CAWCS). To curb this growth, California implemented Assembly Bill 378 (AB 378) in 2012 to regulate physicians' incentives to dispense MFs and CPs. AB 378's regulation on only physician-dispensed MFs and CPs and not pharmacy-dispensed MFs and CPs generated a setting for evaluating the differential effect of the bill on MF and CP use and cost.

OBJECTIVES: To (a) examine the use and cost of MFs and CPs in the CAWCS that are not for inborn errors of metabolism and (b) evaluate the regulatory effect of AB 378.

METHODS: This study adopted a quantitative approach and employed descriptive statistics and t-tests. The analyses used the most recent complete annual claims data from the Workers' Compensation Information System dataset to evaluate MF and CP claims frequencies and dollar amounts reimbursed from 2011 to 2013 and to compare the difference between physician-dispensed and pharmacy-dispensed products.

RESULTS: Of 151,107 MFs and CPs billed, 95,528 (63.2%) prescriptions were reimbursed. The reimbursed MFs and CPs accounted for approximately \$19 million paid to pharmacies and physicians over 3 years. Physician-dispensed MFs, which were regulated by AB 378 in January 2012, experienced a reduction in mean amount reimbursed by \$9.95 ($P < 0.001$)—from \$195.64 to \$185.68—compared with the mean amount reimbursed in 2011. Conversely, physician-dispensed CPs, as well as pharmacy-dispensed MFs and CPs, did not experience a decrease in mean amount reimbursed.

CONCLUSIONS: The results indicated that AB 378 was associated with a statistically significant reduction in physician-dispensed MFs. Concomitantly, the results from t-tests showed no statistically significant difference in mean amount reimbursed for MFs and CPs to pharmacies before and after AB 378. The finding was expected and as hypothesized because AB 378 did not regulate pharmacy-dispensed MFs and CPs. Legislative measures, such as AB 378 in California, may influence rising costs and use of MFs and CPs in general. Other workers' compensation systems could adopt similar legislation to affect the behavior of physician prescribing of non-inborn errors of metabolism MFs and further test these findings.

J Manag Care Spec Pharm. 2018;24(8):819-33

Copyright© 2018, Academy of Managed Care Pharmacy. All rights reserved.

What is already known about this subject

- Medical foods (MFs) often have inadequate scientific support, and public data on the type and number of MFs used and available on the U.S. market today are lacking.
- Despite the absence of data and scientific evidence, insurance claims for MFs—specifically those not for inborn errors of metabolism—are rising.

What this study adds

- This study examined the use and cost of MFs and convenience packages (CPs) in the California Workers' Compensation System, which has not been considered since Assembly Bill 378 (AB 378) went into effect on January 1, 2012.
- The most frequently reimbursed MFs and CPs were for indications of insomnia and pain, with new MFs quickly gaining market share.
- T-tests demonstrated that the difference in amount reimbursed for MFs before and after the implementation of AB 378 was statistically significant, providing support for the effectiveness of AB 378 in regulating MF use.

The availability of medical foods (MFs) is expanding, and increasingly MFs are offered as a treatment choice without evidence of their safety or efficacy. An MF is “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”¹ A convenience-packaged MF (co-pack [CP]) is a generic drug packaged with an MF.

MFs and CPs are dispensed directly from a physician's office or from a pharmacy. MFs are not a food or drug or supplement, but something in between (see list of MFs in Table 1). At the federal level, MFs are regulated partly as a food, but one that requires scientific evidence and a distinct medical need, and partly as a drug, but one that does not require clinical trial evidence for efficacy and safety for approval by the U.S. Food and Drug Administration (FDA). Consequently, many of the MFs on the market lack evidence to support their safety and efficacy.² While state-level actors, such as workers' compensation (WC) systems, can regulate the use of MFs, as many as

45 out of the 50 state WC systems do not have specific regulations on payment for MFs and CPs.

Sales for MFs are projected to exceed \$2 billion in the United States, with an annual growth rate of 10%.³ Several studies have highlighted the rapid growth of MF and CP use within the California Workers' Compensation System (CAWCS), suggesting the importance of tracking their reimbursement mechanisms and amounts.^{4,5} MFs are indispensable for individuals with inborn errors of metabolism (IEMs)—an inherited biochemical disorder in which a specific enzyme defect interferes with metabolism of protein, fat, or carbohydrate. However, the documented increase in MF use within CAWCS is for MFs not used for IEM—despite the absence of data and scientific evidence—and thus deserves assessment of their use and costs.⁶

CAWCS currently uses the Centers for Medicare & Medicaid Services (CMS) weekly National Drug Code (NDC) lowest price list to benchmark prices for covered drugs. However, this system excludes MFs, leaving CMS without benchmark prices for MFs or CPs. This lack of pricing guidance creates a financial incentive for physicians, who legally are authorized to dispense pharmaceutical products in WC systems, to prescribe non-IEM MFs, and may play a role in the documented growth in MF use. To curb this growth, California passed Assembly Bill 378 (AB 378) in 2011 and implemented the bill in 2012 to regulate physicians' incentives.⁷

The combination of the growing use of only non-IEM MFs in CAWCS and the new regulation makes CAWCS an ideal sample for studying MF and CP use. No study has examined comprehensively the use and cost of MFs and CPs in CAWCS since AB 378 came into effect on January 1, 2012.

The main objectives of this study were to (a) examine the use and cost of non-IEM MFs and CPs in CAWCS and (b) evaluate the regulatory effect of AB 378. Specifically, employing the CAWCS claims dataset, the first aim was to determine the specific names of non-IEM MFs reimbursed; if the use of non-IEM MFs and CPs was increasing between 2011 and 2013; and if there were any changes in their cost during that time frame. The second aim was to evaluate if AB 378 influenced the frequency of claims and reimbursed amounts of non-IEM MFs and CPs, especially for the physician-dispensed goods, which AB 378 targets, and compared with the pharmacy-dispensed MFs and CPs, which were not targeted.

Methods

Data

The research design and data use were approved by the institutional review board of the University of California, San Francisco. The analyses employed the most recent complete annual claims data from the Workers' Compensation Information System (WCIS) dataset from CAWCS to evaluate MF and CP claims frequencies and dollar amounts reimbursed from 2011 to 2013.

The unit of analysis (each row) for the database was by prescription claimed, and the database contained the following variables: claim identifiers, billing identifiers, paid (reimbursed) amounts in U.S. dollars, service adjustment codes, drug names, NDC numbers, service dates, and quantity dispensed (days covered) for each billed pharmaceutical product. Each claim represented a single prescription. Each patient in the CAWCS was assigned a unique claim identifier, and each unique bill was identified as either pharmacy or physician dispensed. Service adjustment codes indicated reasons for discrepancy between billed and paid (reimbursed) amounts; the variable allowed us to categorize each claim line (representing a unique prescription) into reimbursed, denied, adjusted, or duplicate bill. Duplicates and negative paid amounts were removed from the dataset.

A specific procedure was followed to identify MFs and CPs in our dataset. An MF should not have an NDC number, with FDA guidance stating that the presence of an NDC number on a food product misbrands the product.¹ Despite the guidance, all the MFs and CPs in the WCIS dataset were designated with an NDC number, which is required for reimbursement.

This study therefore identified a prescription as an MF or a CP claim in the WCIS dataset by examining (a) the NDC description online, (b) the product website, (c) the package insert, and (d) the RED BOOK description. During the identification process, MF ingredients and MF indications were also evaluated; all MFs and CPs in the database were non-IEM MFs and CPs, as they were prescribed to working adults and related to a work injury.

The main policy intervention was statute AB 378,⁷ because one of its legislative intents was to address the increasing use of MFs and CPs through (a) implementing fee schedules limiting payment amount and (b) regulating physicians' financial incentives when prescribing and dispensing MFs and CPs.

Analysis

The analyses for physician-dispensed and pharmacy-dispensed MFs and CPs claims were conducted separately because physician-dispensed MFs and CPs were regulated by AB 378 starting in January 2012, while pharmacy-dispensed MFs and CPs were not specifically regulated by AB 378. The results provided MF and CP claims frequencies and descriptive statistics on paid costs; i.e., reimbursed amount, including frequencies, means, and medians.

T-tests were employed first to determine if there was a statistically significant difference in the mean amount reimbursed per claim for physician-dispensed MFs and CPs before (January 1, 2011–December 31, 2011) and after (January 1, 2012–December 31, 2013) the implementation of AB 378. This study hypothesized that there should be a significant difference, as AB 378 specifically regulated physician-dispensed MFs and CPs. The second t-test evaluated if there was a

Use and Costs of Medical Foods and Convenience-Packaged Drugs in the California Workers' Compensation System

TABLE 1 Medical Foods by Dispenser from 2011 to 2013

Medical Foods ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage Reimbursed ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^f	Standard Deviations ^g
Dispensed by Physicians						
2011-2013						
Theramine	Chronic low back pain/inflammation	34,960	48.52	8,539,928.95	244.28	243.44
Sentra PM	Insomnia	12,733	17.67	1,628,585.24	127.90	122.30
Sentra AM	Insomnia	7,396	10.26	999,937.92	135.20	167.46
GABAdone	Insomnia	5,687	7.89	763,457.23	134.25	111.93
Trepadone	Joint disorder pain/inflammation	2,909	4.04	786,722.58	270.44	269.04
Proteolin	Joint disorder pain/inflammation	2,635	3.66	340,316.26	129.15	84.92
Somnicin	Insomnia	1,988	2.76	196,663.86	98.93	135.25
Apptrim	Obesity	1,810	2.51	293,289.50	162.04	173.22
Sinralyne-PM	Insomnia	744	1.03	42,465.08	57.08	49.85
Limbrel	Osteoarthritis	354	0.49	44,081.14	124.52	152.87
Hypertensa	Hypertension	260	0.36	33,493.29	128.82	192.95
Deplin	Major depression	170	0.24	17,773.79	104.55	68.59
L-Methylfolate	Depression, anemia, renal impairment	101	0.14	7,010.21	69.41	43.24
Metanx	Neuropathic pain	66	0.09	4,055.11	61.44	56.22
Folbic	Atherosclerosis	65	0.09	1,415.09	21.77	17.83
Percura	Peripheral neuropathy	53	0.07	14,188.70	267.71	257.27
Foltx	Hyperhomocysteinemia	35	0.05	1,350.55	38.59	11.92
Folbee	Kidney failure	22	0.03	530.48	24.11	7.97
Foltanx	Diabetic neuropathy	14	0.02	1,064.32	76.02	3.72
Virilex	Fertility	10	0.01	777.29	77.73	61.89
Cerefolin	Cognitive impairment, hyperhomocysteinemia	9	0.01	565.65	62.85	59.62
Ferrex	Iron deficiency, anemia	8	0.01	109.60	13.70	0.00
FABB	Nutrition in cystic fibrosis	5	0.01	201.98	40.40	17.39
Ferocon	Anemia	4	0.01	103.48	25.87	4.78
Glucerna	Impaired glucose tolerance	4	0.01	405.27	101.32	151.20
VSL#3	Ulcerative colitis	4	0.01	71.20	17.80	14.30
Enlyte	Depression	3	0.00	304.41	101.47	0.00
Pulmona	Pulmonary hypertension	3	0.00	670.52	223.51	78.53
Folcaps	Digestive disorders	2	0.00	33.80	16.90	0.00
Total		72,054	100.00	13,719,572.50	190.41	185.10
2011						
Theramine	Chronic low back pain/inflammation	18,580	54.34	4,406,459.21	237.16	226.42
Sentra PM	Insomnia	5,958	17.43	765,383.15	128.46	124.77
Sentra AM	Insomnia	3,759	10.99	550,222.97	146.37	189.50
GABAdone	Insomnia	2,632	7.70	346,742.30	131.74	113.32
Trepadone	Joint disorder pain/inflammation	1,275	3.73	370,477.43	290.57	297.52
Apptrim	Obesity	797	2.33	125,567.87	157.55	164.45
Proteolin	Joint disorder pain/inflammation	591	1.73	60,997.62	103.21	83.00
Limbrel	Osteoarthritis	228	0.67	33,543.56	147.12	177.85
Sinralyne-PM	Insomnia	166	0.49	14,069.79	84.76	59.72
Hypertensa	Hypertension	59	0.17	8,836.19	149.77	165.73
Deplin	Major depression	46	0.13	3,176.58	69.06	49.16
Metanx	Neuropathic pain	34	0.10	1,439.22	42.33	46.33
Folbic	Atherosclerosis	33	0.10	445.77	13.51	15.05
Foltx	Hyperhomocysteinemia	15	0.04	593.47	39.56	17.75
L-Methylfolate	Depression, anemia, renal impairment	6	0.02	393.06	65.51	0.00
Virilex	Fertility	4	0.01	277.44	69.36	80.09
Cerefolin	Cognitive impairment, hyperhomocysteinemia	3	0.01	0.00	0.00	0.00
FABB	Nutrition in cystic fibrosis	2	0.01	42.92	21.46	0.00
Pulmona	Pulmonary hypertension	2	0.01	492.35	246.18	96.17

continued on next page

TABLE 1 Medical Foods by Dispenser from 2011 to 2013 (continued)

Medical Foods ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage Reimbursed ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^f	Standard Deviations ^g
2011						
Folbee	Kidney failure	1	0.00	24.33	24.33	—
VSL#3	Ulcerative colitis	1	0.00	2.15	2.15	—
Total		34,192	100.00	6,689,187.38	195.64	206.96
2012						
Theramine	Chronic low back pain/inflammation	9,629	47.00	2,424,080.55	251.75	232.89
Sentra PM	Insomnia	3,372	16.46	461,942.07	136.99	117.40
Proteolin	Joint disorder pain/inflammation	1,718	8.39	233,257.74	135.77	82.94
Sentra AM	Insomnia	1,585	7.74	212,144.28	133.84	143.51
GABAdone	Insomnia	1,567	7.65	233,444.38	148.98	110.67
Trepadone	Joint disorder pain/inflammation	935	4.56	248,600.52	265.88	247.57
Apptrim	Obesity	608	2.97	108,608.62	178.63	176.83
Somnicin	Insomnia	411	2.01	50,246.11	122.25	136.17
Sinralyne-PM	Insomnia	355	1.73	19,514.22	54.97	42.70
Hypertensa	Hypertension	76	0.37	10,397.97	136.82	198.87
Deplin	Major depression	75	0.37	7,197.31	95.96	50.78
Limbrel	Osteoarthritis	65	0.32	4,831.72	74.33	100.71
L-Methylfolate	Depression, anemia, renal impairment	33	0.16	2,303.98	69.82	43.21
Foltx	Hyperhomocysteinemia	13	0.06	459.64	35.36	3.62
Folbee	Kidney failure	11	0.05	264.18	24.02	1.04
Metanx	Neuropathic pain	11	0.05	1,349.96	122.72	27.72
Folbic	Atherosclerosis	8	0.04	202.96	25.37	17.52
Ferrex	Iron deficiency, anemia	6	0.03	82.20	13.70	0.00
FABB	Nutrition in cystic fibrosis	2	0.01	109.20	54.60	0.00
Folcaps	Digestive disorders	2	0.01	33.80	16.90	0.00
VSL#3	Ulcerative colitis	2	0.01	32.20	16.10	0.00
Glucerna	Impaired glucose tolerance	1	0.00	319.95	319.95	—
Pulmona	Pulmonary hypertension	1	0.00	178.17	178.17	—
Total		20,486	100.00	4,019,601.73	196.21	197.11
2013						
Theramine	Chronic low back pain/inflammation	6,751	38.85	1,709,389.19	253.21	256.68
Sentra PM	Insomnia	3,403	19.58	401,260.02	117.91	122.06
Sentra AM	Insomnia	2,052	11.81	237,570.67	115.78	137.09
Somnicin	Insomnia	1,577	9.08	146,417.75	92.85	134.38
GABAdone	Insomnia	1,488	8.56	183,270.55	123.17	109.21
Trepadone	Joint disorder pain/inflammation	699	4.02	167,644.63	239.83	237.24
Apptrim	Obesity	405	2.33	59,113.01	145.96	182.63
Proteolin	Joint disorder pain/inflammation	326	1.88	46,060.90	141.29	89.39
Sinralyne-PM	Insomnia	223	1.28	8,881.07	39.83	43.36
Hypertensa	Hypertension	125	0.72	14,259.13	114.07	201.32
L-Methylfolate	Depression, anemia, renal impairment	62	0.36	4,313.17	69.57	45.65
Limbrel	Osteoarthritis	61	0.35	5,705.86	93.54	36.81
Percura	Peripheral neuropathy	53	0.31	14,188.70	267.71	257.27
Deplin	Major depression	49	0.28	7,399.90	151.02	82.45
Folbic	Atherosclerosis	24	0.14	766.36	31.93	16.29
Metanx	Neuropathic pain	21	0.12	1,265.93	60.28	60.49
Foltanx	Diabetic neuropathy	14	0.08	1,064.32	76.02	3.72
Folbee	Kidney failure	10	0.06	241.97	24.20	12.13
Foltx	Hyperhomocysteinemia	7	0.04	297.44	42.49	0.87
Cerefolin	Cognitive impairment, hyperhomocysteinemia	6	0.03	565.65	94.28	46.19
Virilex	Fertility	6	0.03	499.85	83.31	54.34
Ferocon	Anemia	4	0.02	103.48	25.87	4.78
Enlyte	Depression	3	0.02	304.41	101.47	0.00

continued on next page

TABLE 1 Medical Foods by Dispenser from 2011 to 2013 (continued)

Medical Foods ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage Reimbursed ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^f	Standard Deviations ^g
2013						
Glucerna	Impaired glucose tolerance	3	0.02	85.32	28.44	49.26
Ferrex	Iron deficiency, anemia	2	0.01	27.40	13.70	0.00
FABB	Nutrition in cystic fibrosis	1	0.01	49.86	49.86	–
VSL#3	Ulcerative colitis	1	0.01	36.85	36.85	–
Total		17,376	100.00	3,010,783.39	97.97	205.05
Dispensed by Pharmacies						
2011-2013						
Somnicin	Insomnia	1,000	24.99	123,731.26	123.73	149.63
Theramine	Chronic low back pain/inflammation	692	17.29	225,143.43	325.35	318.33
Limbrel	Osteoarthritis	368	9.20	35,599.65	96.74	64.20
Proteolin	Joint disorder pain/inflammation	309	7.72	39,346.52	127.34	93.16
Deplin	Major depression	231	5.77	25,207.79	109.12	72.62
L-Methylfolate	Depression, anemia, renal impairment	200	5.00	17,398.49	86.99	45.88
Sentra PM	Insomnia	194	4.85	35,237.05	181.63	125.80
GABAdone	Insomnia	191	4.77	13,159.21	68.90	113.00
Sinralyne-PM	Insomnia	190	4.75	4,980.41	26.21	45.62
Metanx	Neuropathic pain	150	3.75	13,684.29	91.23	79.72
Apptrim	Obesity	106	2.65	24,467.29	230.82	202.81
Trepadone	Joint disorder pain/inflammation	89	2.22	28,797.50	323.57	326.36
Sentra AM	Insomnia	82	2.05	22,723.12	277.11	266.20
Folbic	Atherosclerosis	79	1.97	2,039.45	25.82	19.11
Cerefolin	Cognitive impairment, hyperhomocysteinemia	48	1.20	5,249.46	109.36	71.28
Foltanx	Diabetic neuropathy	14	0.35	1,099.63	78.55	0.45
VSL#3	Ulcerative colitis	13	0.32	1,678.49	129.11	126.73
Foltx	Hyperhomocysteinemia	12	0.30	173.10	14.43	15.07
FABB	Nutrition in cystic fibrosis	10	0.25	246.60	24.66	6.75
Ferocon	Anemia	10	0.25	239.06	23.91	4.45
Folcaps	Digestive disorders	6	0.15	70.98	11.83	0.00
Hypertensa	Hypertension	5	0.12	712.41	142.48	318.60
Ferrex	Iron deficiency, anemia	2	0.05	126.72	63.36	54.87
Glucerna	Impaired glucose tolerance	1	0.02	164.63	164.63	–
Total		4,002	100.00	621,276.54	155.24	200.72
2011						
Theramine	Chronic low back pain/inflammation	349	30.91	94,184.25	269.87	324.89
Limbrel	Osteoarthritis	181	16.03	17,314.88	95.66	65.16
Deplin	Major depression	124	10.98	12,179.08	98.22	79.67
Sentra PM	Insomnia	97	8.59	17,618.92	181.64	131.95
GABAdone	Insomnia	81	7.17	6,298.37	77.76	116.35
Apptrim	Obesity	55	4.87	9,575.59	174.10	187.65
Trepadone	Joint disorder pain/inflammation	46	4.07	15,348.01	333.65	370.42
Proteolin	Joint disorder pain/inflammation	39	3.45	3,043.94	78.05	86.04
Metanx	Neuropathic pain	38	3.37	1,642.96	43.24	39.69
L-Methylfolate	Depression, anemia, renal impairment	33	2.92	2,336.20	70.79	24.32
Sentra AM	Insomnia	29	2.57	8,982.81	309.75	174.97
Folbic	Atherosclerosis	21	1.86	659.17	31.39	20.74
Ferocon	Anemia	10	0.89	239.06	23.91	4.45
Folcaps	Digestive disorders	6	0.53	70.98	11.83	0.00
Foltx	Hyperhomocysteinemia	6	0.53	173.10	28.85	0.00
Cerefolin	Cognitive impairment, hyperhomocysteinemia	5	0.44	621.77	124.35	66.01
VSL#3	Ulcerative colitis	4	0.35	649.02	162.26	228.98
Hypertensa	Hypertension	3	0.27	0.00	0.00	0.00
Ferrex	Iron deficiency, anemia	1	0.09	24.56	24.56	–

continued on next page

Use and Costs of Medical Foods and Convenience-Packaged Drugs in the California Workers' Compensation System

TABLE 1 Medical Foods by Dispenser from 2011 to 2013 (continued)

Medical Foods ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage Reimbursed ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^f	Standard Deviations
2011						
Glucerna	Impaired glucose tolerance	1	0.09	164.63	164.63	—
Total		1,129	100.00	191,127.00	169.29	231.40
2012						
Somnicin	Insomnia	288	20.18	31,003.56	107.65	133.32
Proteolin	Joint disorder pain/inflammation	218	15.28	28,216.50	129.43	91.05
Theramine	Chronic low back pain/inflammation	210	14.72	73,564.44	350.31	237.98
Limbrel	Osteoarthritis	109	7.63	9,921.00	91.02	66.44
GABAdone	Insomnia	92	6.45	4,291.07	46.64	94.44
Sinralyne-PM	Insomnia	90	6.31	3,740.25	41.56	44.11
L-Methylfolate	Depression, anemia, renal impairment	78	5.46	7,426.12	95.21	48.72
Deplin	Major depression	70	4.91	8,840.69	126.30	74.47
Metanx	Neuropathic pain	59	4.13	5,763.84	97.69	70.69
Sentra PM	Insomnia	55	3.86	9,969.68	181.27	112.85
Folbic	Atherosclerosis	36	2.52	877.13	24.36	21.81
Apptrim	Obesity	35	2.45	8,589.13	245.40	151.62
Cerefolin	Cognitive impairment, hyperhomocysteinemia	30	2.11	3,417.68	113.92	65.97
Trepadone	Joint disorder pain/inflammation	24	1.68	8,501.40	354.23	274.91
Sentra AM	Insomnia	20	1.40	4,883.82	244.19	279.91
Foltx	Hyperhomocysteinemia	6	0.42	0.00	0.00	21.81
VSL#3	Ulcerative colitis	6	0.42	541.60	90.27	49.24
Hypertensa	Hypertension	1	0.07	712.41	712.41	—
Total		1,427	100.00	210,260.00	147.00	168.35
2013						
Somnicin	Insomnia	712	49.24	92,727.70	130.24	155.36
Theramine	Chronic low back pain/inflammation	133	9.20	57,394.74	431.54	376.86
Sinralyne-PM	Insomnia	100	6.92	1,240.16	12.40	42.63
L-Methylfolate	Depression, anemia, renal impairment	89	6.15	7,636.17	85.80	48.05
Limbrel	Osteoarthritis	78	5.39	8,363.77	107.23	58.01
Metanx	Neuropathic pain	53	3.67	6,277.49	118.44	95.02
Proteolin	Joint disorder pain/inflammation	52	3.60	8,086.08	155.50	94.52
Sentra PM	Insomnia	42	2.90	7,648.45	182.11	130.21
Deplin	Major depression	37	2.56	4,188.02	113.19	19.40
Sentra AM	Insomnia	33	2.28	8,856.49	268.38	323.02
Folbic	Atherosclerosis	22	1.52	503.15	22.87	10.48
Trepadone	Joint disorder pain/inflammation	19	1.31	4,948.09	260.43	274.67
GABAdone	Insomnia	18	1.24	2,569.77	142.77	149.74
Apptrim	Obesity	16	1.11	6,302.57	393.91	261.53
Foltanx	Diabetic neuropathy	14	0.97	1,099.63	78.55	0.45
Cerefolin	Cognitive impairment, hyperhomocysteinemia	13	0.90	1,210.01	93.08	86.59
FABB	Nutrition in cystic fibrosis	10	0.69	246.60	24.66	6.75
VSL#3	Ulcerative colitis	3	0.21	487.87	162.62	56.93
Ferrex	Iron deficiency, anemia	1	0.07	102.16	102.16	—
Hypertensa	Hypertension	1	0.07	0.00	0.00	—
Total		1,446	100.00	219,889.00	152.00	203.86

^aName of medical food indicated on claims.

^bIndication of medical food.

^cNumber of claims reimbursed.

^dPercentage out of all reimbursed medical food during the time frame.

^eTotal amount reimbursed for the medical food during the time frame in U.S. dollars.

^fMean amount reimbursed for the medical food during the time frame in U.S. dollars.

^gStandard deviation from the mean amount reimbursed for the medical food during the time frame.

difference in mean amount reimbursed per claim for pharmacy-dispensed MFs and CPs before and after the implementation of AB 378; it was hypothesized that there should be no statistically significant difference, as AB 378 did not regulate pharmacy-dispensed MFs and CPs.

Results

The CAWCS database contained a total of 20,373,477 claims during the study period of January 1, 2011, through December 31, 2013. Of these, 4,641 claims were for dispensing fees and 7,838,859 claims were for medical devices and supplies. The remaining 12,529,977 claims were for pharmaceutical products. MFs and CPs represented approximately 151,000 out of 20 million total claims (each representing a prescription) dispensed in CAWCS across all 3 years of the study, or about 51,000 prescriptions annually.

Of all MF and CP prescriptions, 95% were physician-dispensed (5% were pharmacy-dispensed). Out of 151,107 MFs and CPs dispensed by both physicians and pharmacies, 95,528 (63.2%) prescriptions were reimbursed. Of the 95,528 reimbursed prescriptions, 76,056 were MF prescriptions and 19,482 were CP prescriptions. Physicians dispensed 54 different MFs and CPs, and pharmacies dispensed 46 different MFs and CPs. The reimbursed MFs and CPs accounted for approximately \$19 million paid over the 3 years. Of the total amount paid by CAWCS, \$18.5 million (96.4%) was paid to physicians and \$682,000 (3.6%) was paid to pharmacies.

Table 1 contains the number of prescriptions and per prescription cost of MFs reimbursed by CAWCS by named MF and by dispenser (physician or pharmacy) from 2011 to 2013. The most prescribed MF by physicians was Theramine for chronic low back pain and by pharmacies was Somnicin for insomnia. The top 4 MFs for both dispensers were all for either insomnia or inflammatory pain relief. Physicians' most frequently reimbursed MF was Theramine (48.5%), followed by Sentra PM (17.7%), Sentra AM (10.3%), and GABAdone (7.9%), all for insomnia. The fifth and sixth most reimbursed MFs were for joint inflammatory pain: Trepadone (4.0%) and Proteolin (3.7%). Following MFs for pain were Somnicin (2.8%) for insomnia, Apptrim (2.5%) for obesity, and others (2.7%) for indications such as osteoarthritis, hypertension, and depression. Theramine alone accounted for \$8.5 million spent, which was more than half of the total amount reimbursed for physician-dispensed MFs. Theramine also had the second highest reimbursed amount per prescription (\$244), slightly under Trepadone (\$270), which also was used for chronic inflammatory pain.

The most frequently reimbursed pharmacy-dispensed MFs was Somnicin (25.0%) for insomnia, followed by Theramine (17.3%) for chronic low back pain, Limbrel (9.2%) and Proteolin (7.7%) for joint inflammatory pain, Deplin (5.8%) for major depression, L-methylfolate (5.0%) for renal impairment,

and Sentra PM (4.9%), GABAdone (4.8%), and Sintralyne-PM (4.8%), all for insomnia. While Somnicin was the most frequently reimbursed pharmacy-dispensed MF, Theramine was the costliest MF, costing CAWCS \$225,143 and \$325 per prescription.

The top reimbursed MFs did not vary greatly by year (Table 1). The only exception was Somnicin, which became the top reimbursed medication in 2012 immediately following its availability on the market.

Table 2 contains the number of CP prescriptions and mean amount reimbursed per prescription by CPs and by dispenser between 2011 and 2013. The most frequently reimbursed physician-dispensed CP was Theraproxen (11.8%) for the indications of inflammation and pain, followed by Gaboxetine (11.7%) for major depressive disorder, Theratramadol (10.7%) for pain, Theraproxen (9.7%) for inflammation, and Prazolamine (9.2%) for painful musculoskeletal conditions. Therapoxophene for pain, with only 5 reimbursed prescriptions, had the highest reimbursed amount per prescription for physician-dispensed CP (\$423.30), and Sentraflo AM-10 for major depressive disorder had the second highest (\$393.79).

The most frequently reimbursed pharmacy-dispensed CP over the 3 years was Theraproxen (16.1%) for inflammation, followed by Theracodophen (13.0%), Theraproxen (10.31%), and Theratramadol (10.31%), which were all for pain. Sentraflo AM-10 had the highest reimbursed amount per prescription (\$811.77) for pharmacy-dispensed CPs. Trepoxen, with only 2 reimbursed prescriptions, had the second highest reimbursed amount per prescription (\$625.95) for pharmacy-dispensed CPs.

While the top reimbursed CPs varied slightly over the years (Table 2), for both physician-dispensed and pharmacy-dispensed CPs, the top medications were for pain management.

A steady reduction was observed in both the yearly number of physician-dispensed MFs (from 54,325 in 2011 to 31,998 in 2012 to 27,201 in 2013), and CPs billed (from 17,605 in 2011 to 8,874 in 2012 to 3,540 in 2013) and the number of reimbursed (paid) physician-dispensed MFs (from 34,192 in 2011 to 20,486 in 2012 to 17,376 in 2013) and CPs (from 11,162 in 2011 to 5,900 in 2012 to 2,197 in 2013). The percentage of physician-dispensed billed prescriptions that were reimbursed remained steady from 62.9% in 2011 to 64.0% in 2012 to 63.9% in 2013. This trend may be indicative that CAWCS did not change its reimbursement pattern, but physicians were simply prescribing and billing fewer MFs (Table 3).

Pharmacy-dispensed MFs and CPs, which were not regulated by AB 378, did not experience a reduction but did experience fluctuation in prescriptions and reimbursements. The yearly number of pharmacy-dispensed MFs billed increased from 1,698 in 2011 to 2,357 in 2012 to 3,056 in 2013, with increased numbers reimbursed from 1,129 in 2011 to 1,427 in 2012 to 1,446 in 2013, while the percentage of the prescriptions that were reimbursed decreased from 66.5% in 2011 to 60.5% in 2012 to 47.3% in 2013.

TABLE 2 Convenience Packages by Dispenser from 2011 to 2013

Co-pack ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^{d,f}	Standard Deviation ^g
Dispensed by Physicians						
2011-2013						
Theraproxen	Inflammation and pain	2,273	11.80	518,198.11	227.98	195.62
Gaboxetine	Major depressive disorder	2,252	11.69	641,056.48	284.66	373.94
Theratramadol	Moderate to severe pain	2,061	10.70	641,733.24	311.37	306.50
Theraproxen	Inflammation	1,870	9.71	437,055.93	233.72	179.39
Prazolamine	Discomfort associated with acute, painful musculoskeletal conditions	1,767	9.17	328,296.51	185.79	154.30
Gabapentin	Active duodenal ulcer	1,680	8.72	464,939.91	276.75	303.70
Therabenzaprine	Muscle spasm, inflammation, pain disorder	1,644	8.54	385,324.99	234.38	205.12
Gabazolamine	Anxiety disorder	1,481	7.69	306,787.70	207.15	218.98
Theracodophen	Moderate to moderately severe pain	1,217	6.32	305,588.41	251.10	198.12
Strazepam	Insomnia	810	4.21	128,730.24	158.93	117.00
Therapentin	Postherpetic neuralgia, partial seizure	650	3.38	238,211.88	366.48	420.14
Lytensopril	Hypertension	365	1.90	53,045.35	145.33	237.16
Appformin	Type II diabetes	228	1.18	48,241.41	211.59	374.41
Hypertensolol	Hypertension	175	0.91	43,584.99	249.06	361.67
Trepoxicam	Osteoarthritis of the knee and hip	151	0.78	44,506.97	294.75	241.38
Sentraflox AM-10	Major depressive disorder, OCD	136	0.71	53,554.97	393.79	376.50
Sentrazolpidem	Insomnia	130	0.68	31,625.94	243.28	268.52
Sentradine	Active duodenal ulcer	110	0.57	23,231.33	211.19	239.51
Trepoxen	Pain disorders, inflammation	70	0.36	16,621.80	237.45	351.19
Theracodeine	Pain disorders, inflammation	64	0.33	11,067.21	172.93	166.07
Trazamine	Sleep disorders	49	0.25	12,592.30	256.99	259.27
Gabazolpidem-5	Insomnia	44	0.23	6,547.96	148.82	220.59
Therapeldamine	Osteoarthritis, rheumatoid arthritis	22	0.11	4,246.33	193.02	151.71
Hypertenipine-2.5	Hypertension	5	0.03	511.80	102.36	135.16
Therapoxyphene	Mild to moderate pain	5	0.03	2,116.51	423.30	258.23
Total		19,259	100.00	4,747,418.27	246.50	244.37
2011						
Prazolamine	Discomfort associated with acute, painful musculoskeletal conditions	1,392	12.47	245,346.77	176.25	143.29
Theraproxen	Inflammation and pain	1,360	12.18	271,581.71	199.69	174.82
Gaboxetine	Major depressive disorder	1,309	11.73	462,521.02	353.34	434.22
Gabazolamine	Anxiety disorder	1,288	11.54	276,142.03	214.40	223.68
Theraproxen	Inflammation	1,237	11.08	275,696.74	222.88	159.89
Theratramadol	Moderate to severe pain	985	8.82	299,860.96	304.43	297.65
Gabapentin	Active duodenal ulcer	826	7.40	212,021.71	256.68	299.19
Therabenzaprine	Muscle spasm, inflammation, pain disorder	805	7.21	205,278.26	255.00	279.60
Theracodophen	Moderate to moderately severe pain	701	6.28	177,649.43	253.42	213.93
Strazepam	Insomnia	332	2.97	54,374.14	163.78	118.02
Therapentin	Postherpetic neuralgia, partial seizure	261	2.34	97,192.74	372.39	363.71
Lytensopril	Hypertension	177	1.59	25,124.07	141.94	243.53
Hypertensolol	Hypertension	127	1.14	20,626.58	162.41	270.51
Sentradine	Active duodenal ulcer	91	0.82	18,509.53	203.40	230.38
Appformin	Type II diabetes	71	0.64	15,346.76	216.15	399.17
Theracodeine	Pain disorders, inflammation	40	0.36	5,167.23	129.18	160.25
Trepoxicam	Osteoarthritis of the knee and hip	34	0.30	10,473.38	308.04	223.57
Sentraflox AM-10	Major depressive disorder, OCD	26	0.23	10,632.20	408.93	411.72
Sentrazolpidem	Insomnia	25	0.22	6,639.24	265.57	271.78
Trazamine	Sleep disorders	24	0.22	7,306.39	304.43	316.35
Trepoxen	Pain disorders, inflammation	19	0.17	7,260.99	382.16	373.35
Therapeldamine	Osteoarthritis, rheumatoid arthritis	14	0.13	1,769.65	126.40	154.71

continued on next page

TABLE 2 Convenience Packages by Dispenser from 2011 to 2013 (continued)

Co-pack ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^{d,f}	Standard Deviation ^g
2011						
Gabazolpidem-5	Insomnia	10	0.09	1,832.20	183.22	208.51
Hypertenipine-2.5	Hypertension	4	0.04	500.68	125.17	144.53
Therapoxyphene	Mild to moderate pain	4	0.04	2,116.51	529.13	119.39
Total		11,162	100.00	2,710,970.92	242.88	267.65
2012						
Theraproxen	Inflammation and pain	771	13.07	197,498.24	256.16	201.33
Therabenzaprine	Muscle spasm, inflammation, pain disorder	739	12.53	150,026.67	203.01	198.19
Theratramadol	Moderate to severe pain	694	11.76	212,840.24	306.69	312.45
Gabididine	Active duodenal ulcer	646	10.95	177,184.39	274.28	302.25
Gaboxetine	Major depressive disorder	603	10.22	116,814.37	193.72	260.38
Theraproxen	Inflammation	502	8.51	121,472.94	241.98	193.87
Theracodophen	Moderate to moderately severe pain	448	7.59	113,562.36	253.49	179.91
Prazolamine	Discomfort associated with acute, painful musculoskeletal conditions	292	4.95	58,749.31	201.20	177.40
Strazepam	Insomnia	243	4.12	38,454.08	158.25	127.35
Therapentin	Postherpetic neuralgia, partial seizure	238	4.03	85,102.39	357.57	503.88
Gabazolamine	Anxiety disorder	192	3.25	30,498.40	158.85	178.06
Lytensoiril	Hypertension	130	2.20	17,546.06	134.97	221.68
Appformin	Type II diabetes	94	1.59	16,523.50	175.78	348.60
Trepoxicam	Osteoarthritis of the knee and hip	64	1.08	18,324.87	286.33	264.85
Sentraflox AM-10	Major depressive disorder, OCD	54	0.92	22,131.30	409.84	382.79
Sentrazolpidem	Insomnia	45	0.76	12,097.35	268.83	323.15
Hypertensolol	Hypertension	38	0.64	14,483.74	381.15	421.68
Trepoxen	Pain disorders, inflammation	26	0.44	3,951.30	151.97	298.20
Gabazolpidem-5	Insomnia	25	0.42	4,002.73	160.11	250.77
Theracodeine	Pain disorders, inflammation	24	0.41	5,899.98	245.83	152.06
Trazamine	Sleep disorders	23	0.39	5,269.55	229.11	182.03
Sentradine	Active duodenal ulcer	5	0.08	670.42	134.08	183.60
Therapentin	Osteoarthritis, rheumatoid arthritis	2	0.03	664.14	332.07	0.00
Hypertenipine-2.5	Hypertension	1	0.02	11.12	11.12	–
Therapoxyphene	Mild to moderate pain	1	0.02	0.00	0.00	–
Total		5,900	100.00	1,423,779.45	241.32	261.77
2013						
Theratramadol	Moderate to severe pain	382	17.39	129,032.04	337.78	317.31
Gaboxetine	Major depressive disorder	340	15.48	61,721.09	181.53	192.40
Strazepam	Insomnia	235	10.70	35,902.02	152.77	103.81
Gabididine	Active duodenal ulcer	208	9.47	75,733.81	364.10	312.11
Therapentin	Postherpetic neuralgia, partial seizure	151	6.87	55,916.75	370.31	364.80
Theraproxen	Inflammation and pain	142	6.46	49,118.16	345.90	273.21
Theraproxen	Inflammation	131	5.96	39,886.25	304.48	261.32
Therabenzaprine	Muscle spasm, inflammation, pain disorder	100	4.55	30,020.06	300.20	308.72
Prazolamine	Discomfort associated with acute, painful musculoskeletal conditions	83	3.78	24,200.43	291.57	198.43
Theracodophen	Moderate to moderately severe pain	68	3.10	14,376.62	211.42	128.68
Appformin	Type II diabetes	63	2.87	16,371.15	259.86	383.06
Sentrazolpidem	Insomnia	60	2.73	12,889.35	214.82	219.54
Lytensoiril	Hypertension	58	2.64	10,375.22	178.88	251.83
Sentraflox AM-10	Major depressive disorder, OCD	56	2.55	20,791.47	371.28	358.89
Trepoxicam	Osteoarthritis of the knee and hip	53	2.41	15,708.72	296.39	226.20
Trepoxen	Pain disorders, inflammation	25	1.14	5,409.51	216.38	363.94
Sentradine	Active duodenal ulcer	14	0.64	4,051.38	289.38	306.37
Hypertensolol	Hypertension	10	0.46	8,474.67	847.47	442.63

continued on next page

TABLE 2 Convenience Packages by Dispenser from 2011 to 2013 (continued)

Co-pack ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^{d,f}	Standard Deviation ^g
2013						
Gabazolpidem-5	Insomnia	9	0.41	713.03	79.23	129.00
Therafeldamine	Osteoarthritis, rheumatoid arthritis	6	0.27	1,812.54	302.09	0.00
Trazamine	Sleep disorders	2	0.09	16.36	8.18	0.00
Gabazolamine	Anxiety disorder	1	0.05	147.27	147.27	—
Total		2,197	100.00	612,667.90	278.87	282.85
Dispensed by Pharmacies						
2011-2013						
Theraprogen	Inflammation	36	16.14	9,342.92	259.53	225.93
Theracodophen	Moderate to moderately severe pain	29	13.00	6,522.39	224.91	213.28
Theraproxen	Inflammation and pain	23	10.31	6,737.76	292.95	180.41
Theratrarnadol	Moderate to severe pain	23	10.31	5,952.43	258.80	335.60
Gabididine	Active duodenal ulcer	19	8.52	5,799.63	305.24	204.34
Therabenzaprine	Muscle spasm, inflammation, pain disorder	16	7.17	1,709.14	106.82	161.29
Strazepam	Insomnia	12	5.38	2,133.05	177.75	125.78
Trepoxicam	Osteoarthritis of the knee and hip	11	4.93	3,498.23	318.02	139.03
Sentraflor AM-10	Major depressive disorder, OCD	6	2.69	4,870.60	811.77	151.59
Theracodeine	Pain disorders and inflammation	6	2.69	1,901.13	316.86	8.62
Appformin	Type II diabetes	5	2.24	1,118.45	223.69	467.91
Gabazolpidem-5	Insomnia	5	2.24	978.99	195.80	185.26
Gaboxetine	Major depressive disorder	5	2.24	1,968.31	393.66	295.05
Gabazolamine	Anxiety disorder	4	1.79	1,706.14	426.54	92.55
Lytensopril	Hypertension	4	1.79	1,174.20	293.55	0.00
Prazolamine	Discomfort associated with acute, painful musculoskeletal conditions	4	1.79	0.00	0.00	0.00
Sentradine	Active duodenal ulcer	4	1.79	0.00	0.00	0.00
Sentrazolpidem	Insomnia	3	1.35	1,573.25	524.42	505.81
Therapentin	Postherpetic neuralgia, partial seizure	3	1.35	1,214.14	404.71	658.53
Trazamine	Sleep disorders	2	0.90	883.24	441.62	204.76
Trepoxen	Pain disorders, inflammation	2	0.90	1,251.90	625.95	0.00
Therafeldamine	Osteoarthritis, rheumatoid arthritis	1	0.45	335.66	335.66	—
Total		223	100.00	60,671.56	272.07	255.38
2011						
Theracodophen	Moderate to moderately severe pain	13	16.67	3,185.69	245.05	263.15
Theratrarnadol	Moderate to severe pain	9	11.54	2,263.08	251.45	334.26
Strazepam	Insomnia	7	8.97	1,079.61	154.23	139.03
Theraprogen	Inflammation	6	7.69	1,774.39	295.73	254.82
Theracodeine	Pain disorders and inflammation	5	6.41	1,566.86	313.37	1.41
Trepoxicam	Osteoarthritis of the knee and hip	5	6.41	1,543.32	308.66	216.57
Gabazolamine	Anxiety disorder	4	5.13	1,706.14	426.54	92.55
Prazolamine	Discomfort associated with acute, painful musculoskeletal conditions	4	5.13	0.00	0.00	0.00
Theraproxen	Inflammation and pain	4	5.13	1,512.64	378.16	35.51
Gabididine	Active duodenal ulcer	3	3.85	1,709.93	569.98	194.93
Gaboxetine	Major depressive disorder	3	3.85	1,760.16	586.72	153.34
Lytensopril	Hypertension	3	3.85	880.65	293.55	0.00
Therabenzaprine	Muscle spasm, inflammation, pain disorder	3	3.85	339.96	113.32	196.28
Gabazolpidem-5	Insomnia	2	2.56	735.43	367.72	169.92
Sentrazolpidem	Insomnia	2	2.56	563.95	281.98	398.77
Trazamine	Sleep disorders	2	2.56	883.24	441.62	204.76
Trepoxen	Pain disorders, inflammation	2	2.56	1,251.90	625.95	0.00
Therafeldamine	Osteoarthritis, rheumatoid arthritis	1	1.28	335.66	335.66	—
Total		78	100.00	23,092.61	296.06	236.42

continued on next page

TABLE 2 Convenience Packages by Dispenser from 2011 to 2013 (continued)

Co-pack ^a	Indication ^b	Prescriptions Reimbursed ^c	Percentage ^d	Total Amount Reimbursed, \$ ^e	Mean Amount Reimbursed, \$ ^{d,f}	Standard Deviations ^g
2012						
Theraprogen	Inflammation	24	21.43	4,927.15	205.30	166.54
Theraproxen	Inflammation and pain	19	16.96	5,225.12	275.01	193.95
Gabritidine	Active duodenal ulcer	14	12.50	3,996.11	285.44	158.42
Therabenzaprine	Muscle spasm, inflammation, pain disorder	13	11.61	1,369.18	105.32	161.50
Theracodophen	Moderate to moderately severe pain	13	11.61	3,303.07	254.08	155.28
Theratramadol	Moderate to severe pain	8	7.14	3,598.86	449.86	365.44
Sentraflox AM-10	Major depressive disorder, OCD	5	4.46	3,749.40	749.88	0.00
Trepoxicam	Osteoarthritis of the knee and hip	5	4.46	1,629.93	325.99	34.96
Sentradine	Active duodenal ulcer	4	3.57	0.00	0.00	0.00
Appformin	Type II diabetes	3	2.68	33.03	11.01	0.00
Gabazolpidem-5	Insomnia	1	0.89	0.00	0.00	—
Gaboxetine	Major depressive disorder	1	0.89	208.15	208.15	—
Ly tensopril	Hypertension	1	0.89	293.55	293.55	—
Theracodeine	Pain disorders and inflammation	1	0.89	334.27	334.27	—
Total		112	100.00	28,667.82	255.96	225.04
2013						
Theraprogen	Inflammation	6	18.18	2,641.38	440.23	331.55
Theratramadol	Moderate to severe pain	6	18.18	90.49	15.08	7.87
Strazepam	Insomnia	5	15.15	1,053.44	210.69	110.40
Theracodophen	Moderate to moderately severe pain	3	9.09	33.63	11.21	0.00
Therapentin	Postherpetic neuralgia, partial seizure	3	9.09	1,214.14	404.71	658.53
Appformin	Type II diabetes	2	6.06	1,085.42	542.71	732.48
Gabazolpidem-5	Insomnia	2	6.06	243.56	121.78	0.00
Gabritidine	Active duodenal ulcer	2	6.06	93.59	46.80	0.01
Gaboxetine	Major depressive disorder	1	3.03	0.00	0.00	—
Sentraflox AM-10	Major depressive disorder, OCD	1	3.03	1,121.20	1,121.20	—
Sentrazolpidem	Insomnia	1	3.03	1,009.30	1,009.30	—
Trepoxicam	Osteoarthritis of the knee and hip	1	3.03	324.98	324.98	—
Total		33	100.00	8,911.13	270.03	374.11

^aName of convenience package indicated on claims.

^bIndication of convenience package.

^cNumber of claims reimbursed.

^dPercentage out of all reimbursed convenience packages during the time frame.

^eTotal amount reimbursed for the convenience package during the time frame in U.S. dollars.

^fMean amount reimbursed for the convenience package during the time frame in U.S. dollars.

^gStandard deviation from the mean amount reimbursed for the convenience package during the time frame.

Co-pack = convenience package; OCD = obsessive compulsive disorder.

Pharmacy-dispensed CPs billed versus those reimbursed experienced an interesting pattern between 2011 and 2013, with the CP prescriptions billed decreasing steadily from 225 in 2011 to 175 in 2012 to 53 in 2013, but the reimbursed number fluctuated from 78 prescriptions in 2011 to 112 in 2012 to 22 in 2013. CAWCS reimbursed a significantly higher percentage of billed CPs in 2012 (64.0%) than in 2011 (34.7%) and in 2013 (62.3%). The pattern signaled a spillover effect in which pharmacies not subject to the regulations of AB 378 were dispensing more MFs because physicians were facing these AB 378 regulations and dispensing fewer MFs.

The amount paid by CAWCS for MFs and CPs was examined to gain a deeper understanding of the changes in physician behavior and the potential spillover effects in response to differential AB 378, which, starting in 2012, applied only to physicians. CAWCS paid \$18,466,990 for physician-dispensed MFs and CPs; this amount accounted for 96% of MF and CP total cost in CAWCS between 2011 and 2013 (Table 3). Pharmacy-dispensed MFs and CPs accounted for the remaining \$0.7 million (4% of total cost). The mean amount reimbursed per prescription across the 3 years for MFs was higher when physician-dispensed (\$190.41, standard deviation [SD] = 203.97) than when pharmacy-dispensed (\$155.24, SD = 200.72). Conversely,

TABLE 3 Billed and Reimbursed Medical Foods and Convenience Packages by Dispenser from 2011 to 2013

Billed, Year	Prescriptions Billed ^a	Reimbursed, Year	Prescriptions Reimbursed ^b	Percentage Reimbursed ^c	Median, \$ ^d	Mean, \$ ^e	Standard Deviation ^f	Total Reimbursed Amount, \$ ^g
Dispensed by Physicians								
MF (2011-2013)	113,524	MF (2011-2013)	72,054	63.5	188.56	190.41	203.97	13,719,572
2011	54,325	2011	34,192	62.9	194.51	195.64	206.96	6,689,187
2012	31,998	2012	20,486	64.0	190.24	196.21	197.11	4,019,602
2013	27,201	2013	17,376	63.9	172.22	173.27	205.05	3,010,783
CP (2011-2013)	30,019	CP (2011-2013)	19,259	64.2	221.05	246.50	267.89	4,747,418
2011	17,605	2011	11,162	63.4	202.70	242.88	267.65	2,710,971
2012	8,874	2012	5,900	66.5	242.45	241.32	261.77	1,423,779
2013	3,540	2013	2,197	62.1	246.77	278.87	282.85	612,668
Total MF+CP								18,466,990
Dispensed by Pharmacies								
MF (2011-2013)	7,111	MF (2011-2013)	4,002	56.3	92.88	155.24	200.72	621,277
2011	1,698	2011	1,129	66.5	97.11	169.29	231.40	191,127
2012	2,357	2012	1,427	60.5	102.96	147.34	168.35	210,260
2013	3,056	2013	1,446	47.3	80.59	152.07	203.86	219,889
CP (2011-2013)	453	CP (2011-2013)	223	49.2	307.82	272.07	255.38	60,672
2011	225	2011	78	34.7	314.40	296.06	236.42	23,093
2012	175	2012	112	64.0	307.82	255.96	225.04	28,668
2013	53	2013	33	62.3	46.79	270.03	374.11	8,911
Total MF+CP								681,948
Total MF+CP All Dispensed								
Billed ^h	151,107		Reimbursed ⁱ	95,538				19,148,938

^aNumber of prescriptions billed (prescriptions claimed).

^bNumber of prescriptions reimbursed.

^cPercentage of prescriptions reimbursed out of total number of prescriptions billed (prescriptions claimed).

^dMedian reimbursed amount per prescription billed (prescriptions claimed).

^eMean reimbursed amount per prescription billed (prescriptions claimed).

^fStandard deviation from the mean.

^gTotal reimbursed amount in U.S. dollars.

^hTotal number of medical food and convenience packages billed.

ⁱTotal number of medical food and convenience packages reimbursed.

CP=convenience package; MF=medical food.

the mean amount reimbursed per CP prescription was lower when physician-dispensed (\$246.50, SD=267.89) than when pharmacy-dispensed (\$272.07, SD=244.38).

The yearly mean amount reimbursed per prescription fluctuated for both physician-dispensed and pharmacy-dispensed MFs and CPs. Physician-dispensed amount reimbursed for MFs fluctuated from \$195.64 (SD=206.96) in 2011 to \$196.21 (SD=197.11) in 2012 to \$173.27 (SD=205.05) in 2013, and CP fluctuated from \$242.88 (SD=267.65) in 2011 to \$241.32 (SD=261.77) in 2012 to \$278.87 (SD=282.85) in 2013. Pharmacy-dispensed MFs also fluctuated from \$169.29 (SD=231.40) in 2011 to \$147.34 (SD=168.35) in 2012 to \$152.07 (SD=203.86) in 2013, and CPs fluctuated from \$296.06 (SD=236.42) in 2011 to \$255.96 (SD=225.04) in 2012 to \$270.03 (SD=374.11) in 2013.

While the yearly mean amount reimbursed per prescription fluctuated, the total reimbursed cost of physician-dispensed MFs (from approximately \$6.69 million in 2011 to \$4.02 million in 2012 to \$3.01 million in 2013) and CPs (from \$2.71 million in 2011 to \$1.42 million in 2012 to \$0.61 million in 2013) had decreased since the implementation of AB 378. This trend provided additional support for the effectiveness of AB 378 in regulating MF and CP use.

There was a different pattern of reimbursement for pharmacy-dispensed MFs and CPs, which was not regulated by AB 378. The total reimbursed cost of pharmacy-dispensed MFs increased from approximately \$191,127 in 2011 to \$210,260 in 2012 to \$219,889 in 2013. The total yearly cost of pharmacy-dispensed CPs fluctuated from \$23,093 in 2011 to \$28,668 in

TABLE 4 T-Tests Examining Difference in Mean of Reimbursed Amount Pre-AB 378 and Post-AB 378

		Prescriptions	Mean Paid Amount, \$	Standard Deviation	t	df	P Value	Mean Difference, \$	Standard Error	95% CI	
Dispensed by Physicians											
	Pre-AB 378	34,192	195.64	206.96							
MF					6.54	72,052	<0.001	9.95	1.52	6.97	12.93
	Post-AB 378	37,862	185.68	201.12							
	Pre-AB 378	11,162	242.88	267.65							
CP					-2.21	19,257	0.027	-8.63	3.91	-16.30	-0.97
	Post-AB 378	8,097	251.51	268.16							
Dispensed by Pharmacies											
	Pre-AB 378	2,556	157.04	198.94							
MF					0.75	4,000	0.452	4.97	6.61	-7.98	17.92
	Post-AB 378	1,446	152.07	203.86							
	Pre-AB 378	190	272.42	230.01							
CP					0.05	221	0.961	2.39	48.27	-92.74	97.52
	Post-AB 378	33	270.03	374.11							

AB 378=Assembly Bill 378; CI=confidence interval; CP=convenience package; df=degree of freedom; MF=medical food; t=T value.

2012 to \$8,911 in 2013. Combining these trends with the fact that CAWCS was reimbursing a lower percentage of pharmacy-dispensed MFs and reimbursing a higher percentage of CPs each year from 2011 to 2013 suggests that there was a shift in dispensing behavior.

The effect of AB 378 on regulating physician-dispensed MFs and CPs was explored. For physician-dispensed MFs, the mean amount reimbursed per prescription was \$195.64 in the pre-AB 378 group and \$185.68 in the post-AB 378 group (Table 4). The mean amount reimbursed decreased by \$9.95, with a t-test result indicating that the difference in mean amount reimbursed was statistically significant ($P<0.001$). This result provided evidence that AB 378 was associated with a significant reduction in the reimbursed amount for physician-dispensed MFs.

For physician-dispensed CP prescriptions, the difference in mean amount reimbursed (\$242.88 in the pre-AB 378 years and \$251.51 in the post-AB 378 years) increased by \$8.63, with a t-test result indicating that the difference was statistically significant ($P=0.027$). While AB 378 had an effect on the cost of MFs, the cost of CPs per prescription continued to rise. The statistically significant increase in the mean amount reimbursed for CP was not as hypothesized.

For pharmacy-dispensed MF prescriptions, the difference in mean amount reimbursed per MF claim (\$157.04 in the pre-AB 378 group and \$152.07 in the post-AB 378 group) was \$4.97, with a t-test indicating that the difference was not statistically significant ($P=0.452$). The t-test for pharmacy-dispensed CP prescriptions demonstrated that the difference in mean amount reimbursed per CP prescription (\$272.42 in the pre-AB 378 group and \$270.03 in the post-AB 378 group) was \$2.39 ($P=0.961$). The results from t-tests showed no statistically significant difference in mean amount reimbursed for MFs and

CPs to pharmacies before and after AB 378; the finding was expected and as hypothesized because AB 378 did not regulate pharmacy-dispensed MFs and CPs.

Discussion

This study is the first to examine the effect of AB 378 on the use of MFs and CPs from 2011 to 2013 and compare the differences in utilization volume and cost between different dispensers. The investigation of the pattern of MF and CP use and costs for physician-dispensed MFs before and after passage of AB 378 found that this legislation had the desired effect of lowering physician prescription of these products. The results found that although MFs and CPs accounted for only 1.2% of all billed prescriptions (claims) in CAWCS between 2011 and 2013, physicians dispensed almost all (95%) of those MFs and CPs, which resulted in \$19 million reimbursed in the 3-year period. The most frequently billed MFs and CPs were for indications of insomnia and pain, which would be expected for medication claims in worker's compensation systems.

Both the significant cost and the pattern of use are consistent with the findings in previous studies, which first raised the possible conflict of physicians both prescribing and dispensing MFs and CPs.⁴ This high physician prescription volume is especially concerning because the necessity for and evidence of safety and effectiveness of non-IEM MFs are often also lacking.² This investigation also raised questions about how MFs and CPs—which are not allowed to have NDC numbers—should be priced and paid for, given that most medication billing systems (as does CAWCS) require an NDC number.

The investigation demonstrated that physician-dispensed MFs were costlier than pharmacy-dispensed MFs. The findings are congruent with the current literature, which demonstrated that physicians dispensed 2.99 times more products than

pharmacies and that the medical cost for patients receiving physician-dispensed medications was 39% higher than when patients were not receiving physician-dispensed medications.⁸ Nevertheless, the number of physician-dispensed MFs experienced a downward trend from 2011 to 2013, whereas the number of pharmacy-dispensed MFs fluctuated.

The changes in number of MFs billed and reimbursed may be indicative that AB 378 exerted the desired effect on physician prescribing behavior. The lack of change in rate of reimbursed physician-dispensed MF prescriptions indicated that physicians curbed their prescription numbers without needing CAWCS to deny more claims. The pattern also suggested that a spillover effect existed, in which the nonregulated pharmacies were dispensing more MFs because patients might not have been able to get MF and CP prescriptions from physicians. In response to the spillover effect, the analysis showed that a higher percentage of pharmacy-dispensed MF claims were denied by CAWCS.

To gain further insight on physicians' prescribing behavior, we examined the amount that CAWCS paid for MFs and CPs. While the yearly mean amount reimbursed per prescription fluctuated for both physician-dispensed and pharmacy-dispensed MFs and CPs, the difference in cost per MF prescription before and after the implementation of AB 378 was statistically significant, which provided further support for the positive effect of AB 378 in regulating MF use. In addition, the total cost of physician-dispensed MFs, regulated by AB 378, decreased steadily.

The analysis also found additional evidence for a spillover effect, in which the total yearly cost of pharmacy-dispensed MFs increased steadily while the total yearly cost of CPs fluctuated. The spillover effect suggested that CAWCS and others seeing rapid expansion of MF use should also move to regulate pharmacy-dispensed non-IEM MFs and CPs to contain overprescribing and overbilling of these products, especially with unproven safety and effectiveness.

The results presented here provide some evidence that AB 378 exerted regulatory effect on physicians' behavior in dispensing MFs but not in dispensing CPs. The change in physician behavior also affected how pharmacies dispensed MFs and CPs. The percentage of MF and CP use may be small relative to overall drug prescriptions, but these products were still costly to CAWCS. AB 378 curbed prescription frequency and cost for physician-dispensed MFs and CPs, but prescription frequency for pharmacy-dispensed MFs, unregulated by AB 378, was still rising.

While legislation such as AB 378 can exert an effect on MF and CP use, it is important also to pay attention to the effect of new emerging MFs and CPs and how these new products may affect overall use of MFs and CPs and the effectiveness of regulations. For example, analysis showed that a new product Somnycin became available in 2012 and immediately became the most frequently reimbursed pharmacy-dispensed product

in 2012 and 2013. The product contains melatonin, 5-hydroxytryptophan, L-tryptophan, vitamin B6, and magnesium. Since 5-hydroxytryptophan is identified as an MF, Somnycin is classified as an MF despite the fact that the manufacturer does not categorize Somnycin as an MF.⁹ Concomitantly, there are no scientific studies supporting the efficacy of Somnycin.

The Office of Disability Guidelines does not recommend the use of Somnycin for pain-induced insomnia.¹⁰ A warning letter from an independent medical review concluded, based on the California Medical Treatment Utilization Schedule, that Somnycin is neither medically necessary nor appropriate for the treatment of pain-induced insomnia because the condition lacks distinctive nutritional requirements as required for an MF. Somnycin therefore violates the FDA guideline for MFs and should not be reimbursed as an MF by CAWCS. However, due to current federal and state regulation, Somnycin is an MF and accounts for 36% of overall pharmacy-dispensed MFs.

Limitations

While this study took the first step in examining the effect of AB 378, the analyses inevitably had several limitations. First, due to the absence of a list of MFs available, there was no starting standard, leaving room for potential misclassification. To remedy this issue, NDC numbers, packaging information, MF ingredients, and RED BOOK information were evaluated to ensure the accurate classification and incorporation of all MFs and CPs in the dataset.

Second, as with many claims datasets, there were some missing data, duplications, and potential claims errors. The service adjustment code was used to identify duplications and errors and decide if each empty cell was empty due to missing data or simply a zero for billed, reimbursed (paid), denied, or adjusted amount. For example, if an entry was coded as denied by CAWCS, it was assumed that the total amount reimbursed was 0, even if a reimbursed amount was shown. Conversely, if a reimbursed amount was 0, but the service adjustment code indicated that the prescription was reimbursed, the prescription was categorized as paid.

In many cases, the reimbursed amount was 0 because the reimbursement for the prescription line (claim) was included with the reimbursement for the other line. The authors recognized that the 0 entries could sometimes be an indication of error but chose to assume that the service adjustment code provided the most updated information on the claim reimbursement process.

Some entries were missing both drug name and NDC number or contained an invalid NDC number. These products could not be identified or confirmed so (0.4% of all entries) were dropped and likely did not significantly bias our findings due to their small number. In the physician-dispensed dataset, a majority of the claims were missing billed amounts, so these were not reported. Reimbursed amounts were—a more accurate reflection of costs to the claims system, and so they were analyzed for the physician-dispensed analysis.

Finally, the analysis is only the first step to examining the full regulatory effect of AB 378. T-tests were used to examine the difference in cost pre-AB 378 and post-AB 378, but this method did not account for other confounding variables, which the analyses were unable to control for due to the limitation of available variables of interest. It would be beneficial for future analyses to control for additional factors.

Despite these limitations, this study contributed to the understanding of non-IEM MF and CP use for the general population by highlighting the effect of a WC system-specific reimbursement policy and how the policy can curb MF and CP use. The value of MFs and CPs used in patients in WC systems is questionable, given their high costs and lack of robust evidence for efficacy, as reported in 2 previous studies.^{2,4} Wilson et al. (2018) found that most studies on non-IEM MFs were conducted without scientific rigor²; that is, these studies did not employ randomized controlled trials, lacked sufficient sample size, or did not discuss safety and efficacy. Although not addressed specifically here, MFs may also have safety problems, since there is not oversight as to the quality and consistency of their ingredients.

Conclusions

The results of this study demonstrated that MFs dispensed by physicians, which have been regulated by AB 378 since January 2012, experienced a reduction in mean amount reimbursed compared with the mean amount reimbursed in 2011. Legislative measures, such as AB 378 in California, may partly explain the pattern; however, there is a need to begin compiling consistent data on the availability, quality, and need for MFs generally as well as factors influencing MF prescriptions to fully understand the variation in MF use.

Given the rapidly expanding market and clear pricing incentives, the use of MFs and CPs can increase overall and in WC systems—especially because there is little or no oversight on the use or pricing of these products. Other states should look at their own WC systems to evaluate the extent of potentially unrecognized use and costs attributed to MFs and CPs. There is a need for a better understanding of the use of these products within other states' WCs. Future policy efforts should continue to monitor the use and costs of non-IEM MFs as well as focus on how WC claim systems can stay abreast of the need for and safety of non-IEM MFs in a rapidly evolving industry.

DISCLOSURES

Funding for this study was contributed by the California Workers' Compensation System. The authors have nothing to disclose.

REFERENCES

1. U.S. Food & Drug Administration. Frequently asked questions about medical foods; second edition. Guidance for industry. May 2016. Available at: <https://www.fda.gov/downloads/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/UCM500094.pdf>. Accessed June 11, 2018.
2. Wilson L, Lin TK, Oh A, Cao V. A gray area for reimbursement: medical foods for non-born errors of metabolism. *Am J Manag Care*. Forthcoming July 2018.
3. Stephens G. Business insights: the emerging market for medical foods. September 1, 2012. Available at: http://www.nutraceuticalsworld.com/issues/2012-09/view_columns/business-insights-the-emerging-market-for-medical-foods. Accessed June 11, 2018.
4. Wynn BO. Use of compound drugs, medical foods, and co-packs in California's workers' compensation program: an overview of the issues. Prepared for the Commission on Health, Safety and Workers' Compensation. WR-828-CHSWC. RAND Center for Health and Safety in the Workplace. January 2011. Available at: https://www.rand.org/pubs/working_papers/WR828.html. Accessed June 11, 2018.
5. Ireland J, Swedlow A. The cost and utilization of compound drugs, convenience packs and medical foods in California workers' compensation. California Workers' Compensation Institute. CWCI Research Notes. August 2010. Available at: <https://www.cwci.org/document.php?file=1337.pdf>. Accessed June 11, 2018.
6. Pullon R. An introduction to the medical foods industry. May 24, 2013. Available at: <https://www.scribd.com/document/230447302/An-Introduction-to-the-Medical-Foods-Industry>. Accessed June 11, 2018.
7. State of California Legislative Counsel. California Assembly Bill 378. Available at: http://www.leginfo.ca.gov/pub/11-12/bill/asm/ab_0351-0400/ab_378_bill_20110509_amended_asm_v97.html. Accessed June 11, 2018.
8. White JA, Tao X, Artuso RD, Bilinski C, Rademacher J, Bernacki EJ. Effect of physician-dispensed medication on workers' compensation claim outcomes in the state of Illinois. *J Occup Environ Med*. 2014;56(5):459-64.
9. Maximus Federal Services. Independent medical review final determination letter. December 24, 2013. Available at: http://dir.ca.gov/dwc/IMR/IMR-Decisions/IMR-Decisions/IMR%20Decisions/IMR2013_10001-20000/CM13-0018109.pdf. Accessed June 11, 2018.
10. Texas Department of Insurance. Medical fee dispute resolution findings and decision. December 9, 2015. Available at: <http://www.tdi.texas.gov/med-cases/medfee15/m4152935.pdf>. Accessed June 11, 2018.

Authors

TRACY KUO LIN, MSc, PhD, and LESLIE WILSON, PhD,
School of Pharmacy, University of California, San Francisco.

AUTHOR CORRESPONDENCE: Tracy Kuo Lin, MSc, PhD,
533 Parnassus Ave., U12-A, University of California, San Francisco,
San Francisco, CA 94143. Tel.: 415.502.6429; E-mail: tracy.lin@ucsf.edu.